OTC Markets OTCPK - Delayed Quote USD

Ligand Pharmaceuticals Incorporated (LGNZZ)

0.1200

0.0000

(0.00%)

As of May 9 at 12:48:03 PM EDT. Market Open.

Ligand Pharmaceuticals Pick of the Week at Smart Insider Following CEO, CFO Stock Purchases

Ligand Pharmaceuticals (LGND) was Smart Insider's stock pick of the week after the company's Chief E

PREMIUM
MT Newswires 3 days ago

LGNZZ
0.00%
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis will be joined by members of Ligand’s senior management team and board of directors to commemorate several recent company milestones, including two value-creating transactions. “Ringing the Nasdaq Opening Bell marks an exciting milestone in our company’s history. Over the past few

GlobeNewswire 9 days ago

LGND

LGNDZ

LGNXZ
LGND: 1Q:25 Results

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported first quarter 2025 financial and operational results posting revenues of $45.3 million, a 46% rise over prior year levels. Drivers for the result were a seven-fold increase in financial royalty revenue, a 46% increase in Captisol revenue and a 64% increase in Contract

Zacks Small Cap Research 11 days ago

LGNZZ
0.00%
Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Ligand Pharmaceuticals ( NASDAQ:LGND ) First Quarter 2025 Results Key Financial Results Revenue: US$45.3m (up 46% from...

Simply Wall St. 12 days ago

LGND

LGNDZ

LGNXZ
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

Despite a challenging biopharmaceutical environment, Ligand Pharmaceuticals Inc (LGND) reports significant revenue growth and strategic advancements.

GuruFocus.com 14 days ago

LGNZZ
0.00%
Ligand: Q1 Earnings Snapshot

LGND) on Thursday reported a loss of $42.5 million in its first quarter. On a per-share basis, the Jupiter, Florida-based company said it had a loss of $2.21. Earnings, adjusted for non-recurring costs and stock option expense, were $1.33 per share.

Associated Press Finance 15 days ago

LGNZZ
0.00%
Ligand Reports First Quarter 2025 Financial Results

First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today

GlobeNewswire 15 days ago

LGND

LGNDZ

LGNXZ
Ligand to Participate in May Investor Conferences

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright Royalty Company Conference (Virtual). Management will participate in a fireside chat on May 13, 2025 at 3:30 p.m. ET and be available for one-on-one meetings.RBC Capital Markets Global Healthcare Conference (New York). Management will participate in a fireside chat on May

GlobeNewswire 22 days ago

LGND

LGNDZ

LGNXZ
Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount?

Key Insights Ligand Pharmaceuticals' estimated fair value is US$220 based on 2 Stage Free Cash Flow to Equity Ligand...

Simply Wall St. 23 days ago

LGND

LGNDZ

LGNXZ
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Conference Call

GlobeNewswire 29 days ago

LGND

LGNDZ

LGNXZ
LGND: Pelthos To Become Public Company

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) announced that it had identified a suitor to take its subsidiary Pelthos Therapeutics public in an April 17 th press release . Ligand’s subsidiary will combine with the public company Channel Therapeutics (NYSE: CHRO) which is a clinical stage life sciences company developing

Zacks Small Cap Research 30 days ago

LGNZZ
0.00%

CHRO
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fl

GlobeNewswire last month

LGND

LGNDZ

LGNXZ
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Channel Therapeutics Corporation (NYSE:CHRO) on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos) with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel. The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson. Under the merger agreement, Channel will acquire 100% of Pe

Benzinga last month

CHRO

LGNZZ
0.00%
Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

As the U.S. stock market faces a turbulent period with major indices like the Dow Jones and S&P 500 on track for their worst week in two years, concerns about tariffs and economic health continue to dominate investor sentiment. In such uncertain times, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors looking to navigate these challenging conditions.

Simply Wall St. 2 months ago

LGND

LGNDZ

LGNXZ
Ligand to Participate in March Investor Conferences

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami). Management will participate in one-on-one meetings on March 10, 2025. Barclays 27th Annual Global Healthcare Conference (Miami). Management will participate in a fireside chat on Ma

GlobeNewswire 2 months ago

LGND

LGNDZ

LGNXZ
LGND: First Steps into Cell & Gene Therapy

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational results posting revenues of $167 million, a 27% rise over prior year levels. Drivers for the result were a 30% increase in royalty revenues and a 44% increase in contract revenue. Adjusted core earnings per share were $5.74, up from 2023’s

Zacks Small Cap Research 2 months ago

LGNZZ
0.00%
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Despite a GAAP net loss, Ligand Pharmaceuticals Inc (LGND) showcases robust financial health and promising new ventures in its latest earnings call.

GuruFocus.com 2 months ago

LGNZZ
0.00%
Ligand: Q4 Earnings Snapshot

JUPITER, Fla. AP) — Ligand Pharmaceuticals Inc. LGND) on Thursday reported a loss of $31.1 million in its fourth quarter.

Associated Press Finance 2 months ago

LGNZZ
0.00%
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2024, and provided an operating forecast and bu

GlobeNewswire 2 months ago

LGND

LGNDZ

LGNXZ
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors invested $25 million in return for a high-single digit royalty on D-Fi JUPITER, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has closed a royalty financing agreement with Castle Creek Biosciences, Inc. to support the Phase 3 clinical

GlobeNewswire 2 months ago

LGND

LGNDZ

LGNXZ

Performance Overview

Return	LGNZZ	MSCI WORLD (^990100-USD-STRD)
YTD	--	+2.84%
1-Year	--	+10.64%
3-Year	--	+41.11%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ligand Pharmaceuticals Incorporated (LGNZZ)

Ligand Pharmaceuticals Pick of the Week at Smart Insider Following CEO, CFO Stock Purchases

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

LGND: 1Q:25 Results

Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

Ligand: Q1 Earnings Snapshot

Ligand Reports First Quarter 2025 Financial Results

Ligand to Participate in May Investor Conferences

Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount?

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

LGND: Pelthos To Become Public Company

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Top March 2025 Stocks Estimated To Be Trading Below Their Intrinsic Value

Ligand to Participate in March Investor Conferences

LGND: First Steps into Cell & Gene Therapy

Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Ligand: Q4 Earnings Snapshot

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Performance Overview